AlphAIAlphAI — Financial news for AI agents
medicaldevice-network.comOCT 52 min read$GEHC

GE HealthCare agrees to acquire SOFIE Biosciences in $945m deal

GE HealthCare agreed to acquire SOFIE Biosciences for $945m, expected to close in H1 2027. SOFIE specializes in PET radiopharmaceuticals and operates 15 US sites. The deal aims to expand GE HealthCare's US radiopharmaceutical footprint and support products like Flyrcado, a FDA-approved MPI radiopharmaceutical. Analysts view the acquisition as a strategic addition to GE HealthCare's PDx segment, with potential supply and growth benefits.

Original reporting
medicaldevice-network.com
Published Oct 5, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 5:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$GEHC
Bullish
high confidence
Mentioned
$GEHC
Relevance
9/10
AlphAI data visualization · based on medicaldevice-network.com
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The acquisition positions GEHC to capture a larger share of the projected $2.1 bn PET market by 2025 and beyond.

02

Market read

A major M&A move that could reshape the radiopharma landscape and drive GEHC stock higher.

03

What to watch

Regulatory approvals for future radiotracers and potential competition from Siemens Healthineers' expansion.

Relevance 9/10Novelty 9/10Timing: immediate

Background

GE HealthCare is expanding its diagnostics portfolio; PET imaging is a fast‑growing segment of nuclear medicine.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare announced a $945 million all‑cash acquisition of SOFIE Biosciences, expanding its PET radiopharmaceutical manufacturing footprint.

Expected impact

likely upward pressure as investors price in expanded market reach and revenue potential

Evidence & confidence

Large‑scale M&A in a high‑growth niche; market typically rewards strategic expansion in radiopharma.

Market effects

Sector

Strengthens the medical‑device and radiopharma sector, may boost peers with similar PET capabilities.

Regional

Adds to US PET manufacturing capacity, could affect European and Asian competitors.

Global

Highlights continued consolidation in the radiopharmaceutical supply chain worldwide.

Counterpoint

What could challenge this read

Integration risks and capital deployment could strain GEHC's balance sheet, weighing on short‑term earnings.

Key entities

  • Company
    GE HealthCare

    US‑listed medical‑device and diagnostics firm (ticker GEHC).

  • Company
    SOFIE Biosciences

    CMO specializing in PET radiopharmaceuticals, currently owned by Trilantic North America.

Read at source← All news

Also covered by

6 outlets

Related articles

OCT 7
$GEHCHighAI 9/10

GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

gmtoday.com2 min
OCT 7
$GEHCHighAI 9/10

GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

hedgeco.net2 min